Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Evista in premenopausal women with schizophrenia
NCT02354001Phase 4Completed
- Sponsor
- Alfred Health
- Start
- Apr 2011
- Primary completion
- Jan 2019
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of raloxifene in schizophrenia and schizoaffective disorder, sponsored by Alfred Health. Primary endpoint: Positive and Negative Syndrome Scale at 12 weeks. Started Apr 2011; status: completed.
02
Drugs
raloxifene
03
Conditions
schizophreniaschizoaffective disorder
Beyond the preview
Go deeper on NCT02354001.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02354001.